Reportlinker Adds Therapeutics for Memory and Cognition Disord...( Hormones 78 Other Agents 78 TAB...),Health

Hormones 78

Other Agents 78

TABLE 36 OVERVIEW OF MEMORY/COGNITION TREATMENTS 78

TABLE 36 (CONTINUED) 79

TABLE 37 DEVELOPMENT PIPELINE OF MEMORY/COGNITION DRUGS, BY DEVELOPMENT STATUS 79

TABLE 37 (CONTINUED) 80

TABLE 37 (CONTINUED) 81

TABLE 37 (CONTINUED) 82

TABLE 37 (CONTINUED) 83

TABLE 37 (CONTINUED) 84

TABLE 37 (CONTINUED) 85

FIGURE 10 DEVELOPMENT PIPELINE OF MEMORY/COGNITION DRUGS: NUMBER OF PROGRAMS AT EACH CLINICAL STAGE 85

Glutamate 86

Calcium Channels 86

Maxi-K Channels 86

CREB and Phosphodiesterase 87

Acetylcholine 87

Dopamine 87

Serotonin 88

GABA 88

The Cannabinoid System 88

Histamine 89

Neurohormones and Neuropeptides 89

Other Molecular Targets 89

Genome and Stem Cells 90

FUTURE COGNITION ENHANCERS 91

Changes in Society 91

Increasing Knowledge 91

Scientific Limitations 92

Implications 93

Potential Benefits and Harms 93

Health Economics 94

Regulation, Ethics, and Society 94

TABLE 38 OTC TREATMENTS/NATURAL PRODUCTS 95

OTC TREATMENTS 96

Ginkgo 97

GENE THERAPY 98

STIMULANTS 98

Stimulants (Continued) 99

Chapter-5: WORLDWIDE INDUSTRY STRUCTURE

GROWTH DRIVERS 100

TABLE 39 TOP-SELLING MEMORY AND COGNITION DRUGS ($ MILLIONS) 100

AGING POPULATION 100

Aging Population (Continued) 101

OFF-LABEL USE 102

UNDERSTANDING OF MECHANISMS 103

Transcranial Magnetic Stimulation 104

Genetic Modifications 105

GROWTH OBSTACLES 105

UNDERSTANDING OF MECHANISMS 106

TABLE 40 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 106

FIGURE 11 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 106

CO-MORBID DISEASE STATES 107

ACCEPTANC
'/>"/>